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Abstract
Background: Both artemether and artesunate have been shown to be superior to quinine for the treatment of severe 
falciparum malaria in Southeast Asian adults, although the magnitude of the superiority has been greater for 
artesunate than artemether. These two artemisinin derivatives had not been compared in a randomized trial.
Methods: A randomized double blind trial in 370 adults with severe falciparum malaria; 186 received intramuscular 
artesunate (2.4 mg/kg immediately followed by 1.2 mg/kg at 12 hours then 24 hours then daily) and 184 received 
intramuscular artemether (3.6 mg per kilogram immediately followed by 1.8 mg per kilogram daily) was conducted in 
Viet Nam. Both drugs were given for a minimum of 72 hours.
Results: There were 13 deaths in the artesunate group (7 percent) and 24 in the artemether group (13 percent); P = 
0.052; relative risk of death in the patients given artesunate, 0.54; (95 percent confidence interval 0.28-1.02). 
Parasitaemia declined more rapidly in the artesunate group. Both drugs were very well tolerated.
Conclusions: Intramuscular artesunate may be superior to intramuscular artemether for the treatment of severe 
malaria in adults.
Background
Over the past 25 years, the artemisinin derivatives have
been used for the treatment of severe malaria. They are
the most rapidly acting and potent of all the anti-malarial
drugs. They can be given once daily and are safer and eas-
ier to administer compared to quinine. Artemisinin
derivatives are now part of recommended first-line com-
bination treatment for uncomplicated falciparum malaria
everywhere in the tropical world [1]. Recently, the largest
ever randomized trial in severe malaria compared intra-
venous artesunate with intravenous quinine. It enrolled
1,461 patients with severe falciparum malaria in South-
east Asia before it was stopped early by the data and
safety monitoring committee. Artesunate reduced mor-
tality by 35% compared to quinine. The number needed
to treat to save one life ranged from 11 to 20 [2]. As a
result the new World Health Organization recommended
parenteral artesunate as the first choice anti-malarial
treatment of severe malaria in low transmission areas [1].
But the recommendation for higher transmission areas
(i.e. much of Africa) has remained either artemether,
a r t e s u n a t e  o r  q u i n i n e .  T h e  r e a s o n  f o r  t h i s  c o n t i n u e d
equipoise is that there maybe important differences in the
clinical manifestations and evolution of severe malaria
and the treatment responses in African children com-
pared with adults in Southeast Asia. Notably, in a meta-
analysis of randomized trials in severe malaria, intramus-
cular injection of the oil-based artemisinin derivative,
artemether, did reduce mortality in Southeast Asian
adults compared with quinine, but it did not do so in
African children [3]. This raised the possibility that arte-
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mether was not inferior to artesunate for the treatment of
severe falciparum malaria in Southeast Asian adults. The
largest study from South East Asia in this series was a
randomized comparison of artemether and quinine,
which enrolled 560 adults and was conducted in the Hos-
pital for Tropical Diseases, Ho Chi Minh City, Vietnam
[4]. This study reports a subsequent study from this cen-
tre in which artemether was compared with artesunate.
Methods
This was a single centre double blind comparison of
intramuscular artesunate and intramuscular artemether
in patients admitted to the Hospital for Tropical Diseases,
Ho Chi Minh City with severe falciparum malaria. It was
conducted between May 1996 and June 2003. This study
was approved by the Ethical and Scientific Committee of
the Hospital for Tropical Diseases, Ho Chi Minh City. All
study procedures were essentially as reported in previous
studies performed in the Hospital for Tropical Diseases in
patients with severe malaria [4].
Entry criteria
Patients were included in the study if their peripheral-
blood smears had asexual forms of Plasmodium falci-
parum and had at least one of the following severe com-
plications: cerebral malaria (Glasgow Coma Score was
less than 11), renal acute failure (oliguria and serum crea-
tinine > 250 μmol/L), jaundice (total serum bilirubin > 50
μmol/L) with a parasite count of more than 100,000/μL or
with serum creatinine > 250 μmol/L, hypoglycaemia
(blood glucose < 2.2 mmol/L), anaemia (haematocrit <
20%) with a parasite count of more than 100,000/μL,
hyperparasitaemia (parasite count > 500,000/μL), hyper-
lactataemia (plasma lactate > 4 mmol/L), metabolic aci-
dosis (standard base excess > - 5 mmol/L, base deficit <
10 mmol/L) and shock (systolic blood pressure < 80
mmHg with cool extremities).
Informed consent was provided by all studied patients
(or accompanying relative if patient was unconscious).
Patients were not included if they were younger than 14
years, were pregnant in the first trimester , were known
intravenous drug abusers, had received more than 3 g of
quinine or 2 doses of any artemisinin derivatives in the
previous 48 hours before admission, had a past history of
allergy to any artemisinin derivatives, or if known to be
HIV positive.
Management, clinical and parasitological monitoring
A full history was recorded from either the patient or
their relatives. Patients were examined fully on admis-
sion. Baseline blood samples were taken for full blood
count, biochemistry tests (blood urea nitrogen, serum
creatinine, serum bilirubin, aspartate aminotransferase,
alanine transaminase, plasma lactate), blood culture and
malaria parasite counts. Arterial pH and blood gases were
also measured. Chest X-ray was also performed on
admission. Hydration and neurological status were fully
assessed. A urinary catheter was inserted if necessary.
Lumbar puncture was done if Glasgow Coma Score was
below 14. A Gram stain and bacterial culture was per-
formed on all cerebrospinal fluid samples and was ana-
lyzed for protein, glucose, lactate levels and cell counts.
Patients were treated as per standard recommendations
and as previously reported [4]. Briefly blood transfusion
was administered if the haematocrit was below 20 per-
cent, a bolus of 50 ml of 30 percent dextrose was adminis-
tered if hypoglycaemia was identified and a single dose of
phenobarbital (3.5 mg/kg) was give for all patients with a
GCS ≤ 11. Haemofiltration was performed in patients
who developed acute renal failure or severe lactic acidosis
and patients ventilated if they developed respiratory fail-
ure or a syndrome consistent with adult respiratory dis-
tress syndrome (ARDS). Haematocrit and peripheral
blood smears were performed every four hours for the
first 24 hours and every six hours until asexual stages of
parasite were not detected in three consecutive smears.
C l i n i c a l  o b s e r v a t i o n s  w e r e  r e c o r d e d  o n  s t a n d a r d  c a s e
record forms every 4 hours for the first 24 hours, and
every 6 hours subsequently until discharged.
Anti-malarial treatment
Patients were randomized to treatment with either intra-
muscular artesunate or intramuscular artemether. Arte-
sunate (Guilin No 2 Pharmaceutical Factory, Guangxi,
People's Republic of China) was given in a dose of 2.4 mg/
kg body weight on admission, then 1.2 mg/kg was given
daily. Artemether (50 mg per millilitre; Kunming Phar-
maceutical Company, Kunming, People's Republic of
China) was given in a dose of 3.2 mg/kg body weight on
admission, followed by 1.6 mg/kg daily. Both drugs were
given intramuscularly to the anterior thigh until oral
medication could be taken reliably. Oral artesunate was
given in a dose of 2 mg/kg/day to complete a total course
of seven days (including parenteral doses), providing a
total cumulative dose between 17 and 18 mg/kg over
seven days.
Treatment failure was considered if parasitaemia did
not fall by >75% of the admission value within 48 hours
and intravenous quinine (20 mg/kg followed by 10 mg/kg
8 hourly) was given.
Randomization, concealment and treatment allocation
The randomization was generated from random number
tables. Labels with the name of drug for each patient were
put in coded sealed opaque envelopes, and the envelopes
w e r e  r a n d o m i z e d  i n  b l o c k s  o f  2 0 .  O n c e  a  p a t i e n t  w a s
enrolled in the study the envelope was opened. An inde-
pendent team of nurses, not otherwise involved in thePhu et al. Malaria Journal 2010, 9:97
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study or responsible for the care of these patients, open
the envelope, randomized the patient and prepared the
injection. Neither the treating physicians, study doctors
and nurses, or patients knew which anti-malarial drugs
was administered.
Statistical analysis
The study was reviewed continuously by an external
monitor. Results were entered into a database (Microsoft
Excel, Microsoft Corp, USA). Categorical data were ana-
lyzed with a statistical software package (Stata 10, Stata-
Corp, Texas, USA). Chi- square or Fisher's exact test was
used to compare proportions as appropriate. Risk verifi-
cation was expressed with odds ratio (OR) and 95% confi-
dence interval (CI). The original sample size was
calculated on an assumption of a 20% mortality in the
artemether arm and a 50% reduction with artesunate.
Assuming 80% power and 0.05 significance the study
would have needed to recruit 400 patients into each arm
(allowing for 10% loss to follow up). From the year 2000
onwards, the number of patients with severe malaria
declined dramatically and a decision was made prior to
unblinding to stop the study on the grounds of future
futility. At this stage 370 patients had been recruited, 186
in the artesunate arm and 184 in the artemether arm.
Assuming a 20% of mortality in the artemether arm the
study at the time of stopping therefore had a power of
70% to demonstrate an approximate 50% reduction in
absolute mortality.
Results
Between May 1996 and June 2003, 370 patients were
recruited in the study. There was a gradual rise in number
of severe malaria patients admitted to the HTD with peak
in 2000, but after this date there was a sharp drop of
severe malaria patients and a dramatic decline in the
number of malaria patients admitted in the subsequent
two years. Because of this sustained fall in the number of
patients, a decision was made by the investigators on the
grounds of future futility to terminate the study. This was
done prior to unblinding of the treatment allocation. The
baseline characteristics of patients on admission are
shown in Table 1. Both admissive clinical parameter and
laboratory investigation are similar among two random-
ized treatment groups.
Outcome
The overall mortality rate was ten percent (37 of 370
patients). There were 13/186 (7%) deaths in the artesu-
nate (ARTS) treated patients compared with 24/184
(13%) deaths in the artemether (ARTM) treated patients
unadjusted relative risk of death for artesunate = 0.54,
95% CI: 0.28 - 1.02, p = 0.052 (see Table 2). For the cere-
bral malaria subgroup of patients, there was no signifi-
cant difference in this outcome: the unadjusted mortality
in the ARTS group was 12.9 percent (11/85) and was 13.8
percent (12/87) in the ARTM group (RR for artesunate =
0.94, 95% CI: 0.44 - 2.01, p = 0.87). Further exploration in
factors associated with fatal outcome using multiple
logistic regression (see Table 3), patients who received
intramuscular artesunate had an adjusted odds ratio of
0.41 (95% CI: 0.16 - 1.06, p = 0.06) risk of death compared
to treatment with artemether. Other important contribu-
tors associated with death were admission to hospital
after year 2000, increased plasma lactate on admission,
decreased Glasgow coma score, previous treatment with
artemisinin derivatives and rise of white cell count in the
peripheral blood. No significant difference was found in
of the rate of complications between the groups except
for the development of coma after receiving treatment.
The ARTS group was associated with a lower risk (7/94,
6.9%) of developing coma than the ARTM group (15/82,
15.5) RR = 0.45 CI 95%: 0.19 - 1.05, p = 0.056. This may
help explain why the mortality in the former subgroup
was also lower than the latter (2/99 vs. 12/85, RR = 0.16
CI 95% 0.04 - 0.70, p = 0.004).
Causes of death
The causes of death in severe malaria are often not con-
fined to any single factor or complication, as multiple
organ disorder often developed before death. Of the 37
fatal cases, 25 had acute renal failure (24 of this group
underwent dialysis); 28 cases had persistent intractable
shock; 20 cases had spontaneous bleeding mostly from
gastro-intestinal tract; 12 cases had suspected nosoco-
mial co-infection of lung and urinary tract; and eight
cases had pulmonary oedema.
Recovery
Assessment of standard markers of recovery from severe
malaria did not reveal any significant differences between
the treatment groups (see Table 4). However, the ARTS
group was associated with a quicker initial clearance of
parasite from the peripheral blood (median time to 90%
parasite clearance (IQR) (hrs): 16 (12-30) in ARTS and 24
(12-36) in ARTM) (see Table 4 and Figure 1).
Haematologic recovery
There was no significant difference between two groups
in fall of haematocrit after baseline (median percentage
reduction of admissive haematocrit in the ARTS group:
23.1%, IQR (14.3-35.1), range (0-70%) and in the ARTM
group: 21.4%, IQR (12.9-34.7), range (0-70%) p = 0.25), or
in the number of times required blood transfusions (p =
0.19).
Adverse effects
After treatment hypoglycaemia was documented in three
patients in the artesunate group and 5 in the artemetherPhu et al. Malaria Journal 2010, 9:97
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Table 1: Baseline characteristics of patients, according to treatment group.
Parameters Number (ARTS/
ARTM)
Artesunate (ARTS) 
n = 186
Artemether (ARTM) 
n = 184
P value
Age (years)
Median (Range)
32(15-74) 32.5(15-77) 0.33
Sex - Male/Female 133/53 142/42 0.21
Previous treated with quinine for current malaria 
contracted: no. of patients (%)
11(5.9) 15(8.2) 0.4
Previously treated with artemisinin derivatives for 
current malaria episode: no. of patients (%)
114(61.3) 105(57.1) 0.41
Convulsions: no. of patients (%) 13(7.0) 14(7.6) 0.82
Temperature (°C)
Median (Range)
38.1(36.5-40.5) 38.0(36.0-41.0) 0.75
Pulse (rate/min)
Median (Range)
100 (68-150) 100 (60-151) 0.30
Respiratory rate (/min)
Median (Range)
28 (12-60) 28 (18-68) 0.27
Glasgow Coma Score
Median (Range)
11 (3-15) 11 (3-15) 0.61
Glasgow Coma score less than 11: no. of patients (%) 85(45.7) 87(47.3) 0.76
Shock: no. of patients (%) 6(3.2) 10(5.4) 0.30
Hypoglycaemia: no. of patients (%) 1(0.5) 0(0) 1.0
Haematocrit (%)
Median (Range)
32 (10-50) 31 (8-53) 0.42
Parasite count (×103/mm3)
Median (Range)
80.7(0.02-3471) 70.5 (0.02-3534) 0.75
White cell count (×103/mm3)
Median (Range)
173/171 7.93 (1.1-47.6) 8.40 (1.7-27.0) 0.45
Serum creatinine (mg/dL)
Median (Range)
179/176 1.8 (0.6-9.5) 1.7 (0.6-17.0) 0.68
Total bilirubin (mg/dL)
Median (Range)
124/120 5.7 (0.6-39.0) 5.0 (0.6-38.8) 0.40
ALT (U/L)
Median (Range)
155/161 70 (10-1900) 71 (6-414) 0.45
Lactate (mmol/L)
Median (Range)
168/166 3.2 (0.5-17.7) 3.6 (0.5-16.8) 0.85Phu et al. Malaria Journal 2010, 9:97
http://www.malariajournal.com/content/9/1/97
Page 5 of 10
group. No local abscesses, urticaria or rashes were found
in both groups. There were no severe unexpected adverse
events.
Discussion
The treatment of severe malaria has changed in recent
years with the introduction of the artemisinin derivatives.
Until recently, artemether was favoured by World Health
Organization and, therefore, most studies had been con-
ducted with this derivative. In an individual patient data
meta-analysis of randomized trials in severe falciparum
malaria artemether was superior to quinine in Southeast
Asian adults, but not in African children [3]. Unfortu-
nately intramuscular artemether was probably not the
best artemisinin formulation to choose; it is an oil-based
preparation that releases the drug slowly and erratically
particularly in patients with severe acidosis [5,6]. In con-
trast to intramuscular artemether, intramuscular artesu-
nate is almost instantly bioavailable, and absorbed
reliably and rapidly with peak concentrations occurring
within thirty minutes [6-8]. Moreover, artesunate is a
more potent anti-malarial; artesunate and its main active
metabolite dihydroartimisinin have relative in vitro
potencies, in comparison to artemether, of 2.9 and 4.0
respectively [9]. A recent large multicentre trial from
Southeast Asia demonstrated that artesunate reduced
mortality by 35% compared with quinine [2]. This left the
role of artemether uncertain - was it as good as artesu-
nate despite the pharmacokinetic drawbacks, or was it
inferior? This trial set out to answer this question.
The ARTS group was associated with lower risk (7/101,
6.9%) of developing coma after initiation of therapy than
the ARTM group (15/97, 15.5) RR = 0.45 CI 95%: 0.19 -
1.05, p = 0.056. The parasite clearance times were faster
Table 2: Outcomes after treatment with intramuscular artesunate or artemether.
Outcomes ARTS
n = 186
ARTM n = 184 Relative Risk (95% CI) P value
Mortality (%) 13(7.0) 24(13.0) 0.54(0.28-1.02) 0.052
Convulsions (n) 7(3.8) 9(4.9) 0.77(0.29-2.02) 0.59
Required blood 
transfusion (%)
69(37.1) 69(37.5) 0.99(0.76-1.29) 0.94
Renal impairment (%) 111(59.7) 105(57.1) 1.05(0.88-1.24) 0.61
Renal failure (%) 85(45.7) 85(46.2) 0.99(0.79-1.23) 0.92
Required dialysis (%) 52(28) 54(29.3) 0.95(0.69-1.31) 0.77
Hypoglycaemia (%) 7(3.8) 9(4.9) 0.77(0.29-2.02) 0.59
Spontaneous bleeding 
(%)
26(14) 35(19) 0.73(0.46-1.17) 0.19
Shock (%) 22(11.8) 26(14.1) 0.84(0.49-1.42) 0.51
Concomitant infection 
(%)
66(35.5) 75(40.8) 0.87(0.67-1.13) 0.30
Jaundice (%) 144(77.4) 144(78.3) 0.99(0.89-1.1) 0.85
Pulmonary oedema 
(%)
10(5.4) 13(7.1) 0.76(0.34-1.69) 0.5Phu et al. Malaria Journal 2010, 9:97
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in the ARTS treated patients (median 90% reduction PCT
(IQR) (hrs): 16 (12-30) in ARTS and 24 (12-36) in
ARTM). These data may be explained by the pharmacoki-
netic properties of artesunate compared with artemether
and the faster bioavailaibilty of the active metabolites
with artesunate especially in severely ill patients with
marked metabolic acidosis. It also suggests that the first
few hours of effective treatment are very important and
the faster the active drug can be got to the site of action
(the blood) the better. As outlined above after intramus-
cular injection concentrations of artesunate peaked
within 30 minutes of injection, and artesunate was hydro-
lysed immediately and completely to the biologically
active dihydroartemisinin (DHA). Maximum artemether
concentrations occurred at a median of 10 hours and was
associated with a much more erratic and slower conver-
sion t o DHA. Im portan t ly , in a particular subgr oup of
patients with severe metabolic acidosis the absorption
and conversion to DHA was erratic, limited and delayed.
This hypothesis would be consistent with previous phar-
macokinetic work undertaken at the Hospital for Tropical
Diseases [4]. Getting active drug effective against all
stages of the parasites (and thereby reducing or prevent-
ing maturation and reducing sequestration) into the
patient quickly seems crucial. When faced with a patient
with severe malaria the first few minutes and hours may
make a significant difference to their subsequent chances
of survival. Perhaps it is time to learn the lessons from the
cardiologists and aim to administer the most effective,
fast-acting anti-malarial drug into patients as an emer-
gency in the same way as thrombolytic therapy is admin-
istered urgently in patients with myocardial infarction,
where delays of minutes can make a huge difference to
mortality and preservation of myocardium. Getting
patients treated early and then referred quickly through
the health care system as appropriate is crucial. Once in a
hospital, the ability to triage and administer fast-acting,
potent parenteral drugs would seem essential to prevent
the further maturation of parasites, reduce sequestration
and hence prevent consequent complications.
The trial was overtaken by events. Improved malaria
control in Vietnam led to a dramatic decline in the inci-
dence of severe malaria. The Hospital for Tropical Dis-
eases is a referral hospital, which in the early 1990s was
receiving approximately three to five patients each day
with severe malaria. A decade later this had fallen to
approximately one patient per month. This was insuffi-
cient to sustain this trial and so the trial was terminated
before reaching the pre-defined end points. The trial was
stopped with the investigators blind to the allocations
and prior to any analysis of the results.
The result after 370 patients had been randomized
showed a borderline difference in favour of artesunate
(unadjusted relative risk of death for artesunate = 0.54,
95% CI: 0.28 - 1.02, p = 0.052). The superiority of artesu-
nate over artemether is supported by the larger differ-
ences in mortality rates when artesunate was compared
with quinine (35% reduction in mortality), versus arte-
Table 3: Multivariate logistic regression analysis of factors associated with death in severe falciparum malaria patients.
Factors Adjusted Odds Ratio 
(95% CI)
P* value Notes
IM artesunate treatment 0.41(0.16 - 1.06) 0.066 60 out of 370 were not 
included (30 in ATS and 30 in 
ATM) due to missing of lactate 
and/or WBC count)
Year of study (after 2000) 0.14(0.03 - 0.71) 0.017
Each unit higher in Glasgow 
Coma score
0.82(0.72 - 0.93) 0.002
Unit increase in admission 
plasma lactate
1.28(1.15 - 1.43) < 0.001
Each 103 WBC/mm3 rise 1.1(1.02 - 1.18) 0.017
Pre-treatment with 
artemisinin derivatives
0.29(0.11 - 0.82) 0.019
Forward stepwise on conditioned of likelihood change logistic regression (p to enter = 0.075, p to remove = 0.15)Phu et al. Malaria Journal 2010, 9:97
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Table 4: Assessment of recovery after treatment with intramuscular artesunate or artemether.
Parameters ARTS
n = 186
ARTM
n = 184
P value*
hours
Time to parasite clearance
Decrease to 50% of admission value 0.007
Median (Range) 8 (4-42) 8 (2-60)
Decrease to 90% of admission value 0.004
Median (Range) 16 (4-102) 24 (2-152)
Total clearance 0.97
Median (Range) 72 (7-330) 72 (2-204)
Resolution of fever
Time first temperature < 37.5°C 0.99
Median (Range) 30 (0-768) 20 (0-648)
Time of fever clearance 0.27
Median (Range) 108 (0-888) 108 (0-1088)
Time to recovery from coma
Time to Glasgow Coma score of 8† 0.55
Median (Range) 48 (4-2136) 54 (2-2232)
Time to Glasgow Coma score of 11‡ 0.44
Median (Range) 42 (4-2136) 42 (2-2232)
Time to Glasgow Coma score of 15¶ 0.11
Median (Range) 60 (4-2136) 72 (2-2232)
Time to physical recovery
Time before patient able to drink
Median (Range) 30 (0-2136) 42 (0-2232) 0.2
Time before patient able to eat
Median (Range) 42 (0-2136) 46 (0-2232) 0.18
Time before patient able to sit
Median (Range) 78 (0-2136) 90 (0-2232) 0.32
Time before patient able to stand
Median (Range) 96 (0-2136) 114 (0-2232) 0.66
Time before patient able to walk
Median (Range) 102(0-2136) 120 (0-2232) 0.64
Time before patient able to leave 
hospital
Median (Range) 264(7-2136) 288 (2-2232) 0.68
* Log-rank test
† Only patients who decreased in Glasgow Coma score below 8 were included (130 pts, 58 in ATS group and 72 in ATM group)
‡ Only patients who decreased in Glasgow Coma score below 11 were included (204 pts, 93 in ATS group and 111 in ATM group)
¶Only patients who decreased in Glasgow Coma score below 15 were included (274 pts, 134 in ATS group and 140 in ATM group)Phu et al. Malaria Journal 2010, 9:97
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Figure 1 Kaplan-Meier plots of overall survival and remaining parasitaemic estimates.
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mether (a 26% reduction), although these trials were con-
ducted in different sites, with different protocols and
different drug dosages, so are not strictly comparable
[2,3]. There is probably little to choose intrinsically
between these two derivatives in terms of anti-malarial
pharmacodynamics, and so the superiority of artesunate
is likely to derive from its more rapid, and more reliable
absorption and conversion to the active compound dihy-
droartemisin following intramuscular injection particu-
larly in those severely ill patients with marked acidosis.
Both drugs were very well tolerated with little or no dis-
comfort at the injection site, no serious local or systemic
reactions, a low rate of hypoglycaemia (presumably dis-
ease related), and no neurological sequelae. Although
artemether is easier to administer than artesunate, which
is an advantage in busy epidemic settings, it is probably
an inferior drug. Artesunate, administered as an emer-
gency, should be the treatment of choice for severe falci-
parum malaria.
The patients recruited to this trial all had severe falci-
parum malaria as defined by the World Health Organiza-
tion. In terms of standard prognostic clinical markers of
severity these patients were more severe than previously
reported patients recruited into similar studies in Viet-
nam or compared with those patients entered into
regional trials (data not shown) [2,4]. In this trial, how-
ever, the overall mortality was 10% (7% in the ARTS
group and 13% in the ARTM group), which was lower
than anticipated at the start of the trial when a mortality
of 20% in the ARTM was expected from experience and
reported studies. The reduction in mortality in patients
with severe falciparum malaria in this setting is inevitably
multifactorial and it is only possible to hypothesize on
why such a reduction has occurred. The general intensive
care of patients at HTD and across Vietnam has
improved over the last two decades with improvements
in nursing and medical care, earlier identification of renal
failure, acidosis and respiratory failure and increasingly
availability and use of haemofiltration and mechanical
ventilation. These improvements and the increasing use
of the parenteral artemisinin derivatives have lead to a
reduction in the mortality in severe malaria patients at
HTD from 40% (over 70% mortality in those with renal
failure) in 1991 to approximately 5% in 2009 (15% mortal-
ity rate in those with patients with renal failure). This is
despite an apparent increase in the severity of the
patients admitted in recent years. The combination of
urgent treatment with potent anti-malarial drugs and
improved intensive care has had a profound impact on
the mortality rates in severe malaria in this setting.
Conclusion
Intramuscular artesunate may be superior to intramuscu-
lar artemether for the treatment of severe malaria in
adults. Artesunate, administered as an emergency, should
be the treatment of choice for severe falciparum malaria.
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